Tolemy Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tolemy Bio - overview
Established
2024
Location
Cambridge, -, UK
Primary Industry
Biotechnology
About
Tolemy Bio Ltd is a biotechnology company focused on developing AI-enabled solutions for understanding and controlling cellular systems. The company is building an AI-native platform that integrates biological data, computational models, and experimental workflows to support advancements in cell biology and related applications. The company has developed “Orbit”, an AI-native software platform designed to help scientists understand, predict, and direct cellular systems, with initial applications in cell therapy and biomanufacturing. Tolemy Bio raised €1.
4 million in pre-seed funding with participation from Norrsken Evolve, Big Sur Ventures, JME Ventures, Masia, and other investors. The capital is intended to support platform development, team expansion, and early customer engagement.
Current Investors
Big Sur Ventures, JME Ventures, Stealth PE fund
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.tolemy.bio/
Verticals
Cloud Computing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.